findmyKOL

Sridhar Nambi, MD

Basic profile

Saint Barnabas Medical Center

ORCIDNone on fileNPI
RegionLivingston, NJ · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Sridhar Nambi is an Endocrinology/Metabolic physician affiliated with Saint Barnabas Medical Center. OpenAlex indexes 9 publications with 4,219 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
9publications

Distinct works indexed by OpenAlex.

4,219citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

22 Old Short Hills Rd
Suite 201
Livingston, NJ 07039

Telephone

973-535-8870

Provider last certified this registry record 8 Apr 2024.

View the NPPES registry record

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    70.4%
    Biguanide (metformin)16.8%
    Metformin Hcl Er52%Metformin Hcl48%
    Part D70 patients
    Insulin Analog15.8%
    Humalog Kwikpen U-10025%Lantus Solostar25%Toujeo Solostar9%Basaglar Kwikpen U-1007%Novolog Flexpen6%Xultophy 100-3.66%Tresiba Flextouch U-1006%Soliqua 100-335%Tresiba Flextouch U-2004%Humalog4%Levemir Flexpen4%
    Part D<11 patients

    + 8 more classes in this area

  • Hormonal (systemic)

    20.4%
    l-Thyroxine19%
    Levothyroxine Sodium78%Synthroid22%
    Part D120 patients
    Thyroid Hormone Synthesis Inhibitor0.8%
    Methimazole100%
    Part D<11 patients

    + 1 more class in this area

  • Cardiovascular

    7.9%
    Statin5.1%
    Atorvastatin Calcium43%Rosuvastatin Calcium39%Simvastatin18%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)0.8%
    Losartan Potassium100%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)47.1% facility · 52.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”